Trial records
Registry IDs, sponsors, phases, indications, endpoints, enrollment status, and projected completion dates where an official record provides them.
Ibogaine for addiction
Research Tracker
A structured view of clinical-trial records, preclinical work, policy milestones, and the uncertainty that still surrounds ibogaine research.
What this tracker follows
Research on ibogaine is evolving across clinical, preclinical, and regulatory settings. This page separates documented records from claims about access or outcomes, and it should be read alongside Oriel Drift’s broader ibogaine and addiction overview and its practical safety and screening context.
Research programs
Preclinical and early development work can clarify a hypothesis, but it does not by itself establish a treatment’s safety or effectiveness in people.
Policy signals
Regulatory status, study authorization, and clinic availability are separate questions. Each can change on a different timetable.
Clinical trial records need a careful read
For a searchable public record, the most direct starting point is the ClinicalTrials.gov study registry. A listing describes a protocol and reported status; it is not an endorsement, a safety finding, or evidence that a study will proceed on schedule.
Ibogaine-assisted care studies
Ibogaine-related records may concern substance-use conditions, withdrawal, or other indications. Before drawing conclusions, compare the record’s stated population, intervention, outcomes, locations, and dates with any public discussion of the study.
- Registry ID
- Verify directly in the current registry entry.
- Sponsor
- Confirm the organization named in the official listing.
- Phase
- Use the phase shown by the registry; some studies may not use a phase label.
- Indication
- Read the condition and eligibility language exactly as recorded.
- Primary endpoints
- Check the designated primary outcomes and their time frames.
- Enrollment & completion
- Review recruitment status and the projected completion date as current fields.
Why “active” can be an incomplete label
Recruitment, enrollment, and completion dates are administrative fields that may be revised. A completed study may not yet have a published result, while a published paper may address only one portion of a broader program. The FDA’s drug development overview helps distinguish research activity from an approved medical product.
A practical reading sequence
Follow the evidence trail, not the headline
Ibogaine is a psychoactive substance with a complex research history and meaningful safety concerns. The general reference history of ibogaine can orient a reader, but individual trial records and original publications are the better basis for evaluating a specific claim.
For people trying to understand geographic claims, searches for treatment centers near them should be kept separate from questions about a study’s registration, legal status, and clinical oversight.
-
Locate the primary record
Use the registry ID, rather than a promotional description, to identify the stated study design and its current record.
-
Check the reported endpoints
Primary endpoints show what a study was designed to measure. They are not interchangeable with broader claims about recovery or long-term benefit.
-
Look for published methods and results
When available, compare registry details with a peer-reviewed article indexed in the PubMed research database.
-
Separate study status from access
A trial’s existence does not establish local availability, regulatory approval, or appropriateness for any individual.
Policy and international context
Policy milestones are not a single global timeline. U.S. federal scheduling, research authorization, local law, and the operating status of programs outside the U.S. can all differ. The DEA controlled-substances schedule is a useful primary reference for federal classification in the United States.
U.S. research and regulation
A pathway into formal study does not equal market approval. Readers assessing a claimed regulatory update should look for the relevant agency statement, filing, or registry change and note its date.
For a wider evidence lens, Oriel Drift’s review of the ibogaine evidence base keeps regulatory language distinct from clinical findings.
International clinic claims
Country-level legality and clinic-level practices are not the same thing. Reports about ibogaine clinics in Costa Rica should be checked against current local requirements and independent safety information rather than marketing language alone.
For Mexico-specific treatment claims, compare public statements carefully with the context provided by ibogaine treatment in Mexico.
“A projected completion date is a planning field—not a promise of results, approval, or access.”
Questions worth asking of any research claim
Trial information is most useful when the limits are visible. In particular, claims related to trauma should be separated from evidence about addiction; Oriel Drift’s context on ibogaine for PTSD treatment addresses why indication-specific evidence matters.
How can a reader verify a study listing?
Start with the official registry record. Compare its ID, sponsor, status, endpoints, and projected completion date with any publication or sponsor statement. Registry entries can change and should be read as current records rather than guarantees.
Does a listing establish safety or availability?
No. A listing records a protocol and status; it does not establish safety, efficacy, regulatory approval, or suitability for an individual. Ibogaine has material medical risks that require careful, qualified clinical assessment.
What counts as a pivotal study timeline?
There may be no reliable public timetable until a sponsor identifies a defined development path and updates it through formal channels. Estimated dates should be treated as provisional unless an official source confirms a change.
Why track preclinical work separately?
Laboratory and animal research can help explain mechanisms or guide future hypotheses, but it cannot settle the human safety or effectiveness questions that clinical studies are designed to examine.
Keep the context visible
Research can be promising and uncertain at the same time.
Use primary records, note the date, and keep clinical claims separate from regulatory status, commercial availability, and personal medical decisions.